{"title":"Pfizer: COVID vaccine shows “100% efficacy” in adolescents 12-15","link":"https://arstechnica.com/?p=1753451","date":1617200769000,"content":"<div id=\"rss-wrap\">\n<figure class=\"intro-image intro-left\"><img src=\"https://cdn.arstechnica.net/wp-content/uploads/2021/03/GettyImages-1230743617-800x533.jpeg\" alt=\"Jonathan, a 16-year-old teenager, receives a dose of the Pfizer-BioNtech COVID-19 coronavirus vaccine at Clalit Health Services, in Israel's Mediterranean coastal city of Tel Aviv on January 23, 2021. \"><p class=\"caption\" style=\"font-size:0.8em\"><a href=\"https://cdn.arstechnica.net/wp-content/uploads/2021/03/GettyImages-1230743617.jpeg\" class=\"enlarge-link\" data-height=\"3444\" data-width=\"5166\">Enlarge</a> <span class=\"sep\">/</span> Jonathan, a 16-year-old teenager, receives a dose of the Pfizer-BioNtech COVID-19 coronavirus vaccine at Clalit Health Services, in Israel's Mediterranean coastal city of Tel Aviv on January 23, 2021.  (credit: <a rel=\"nofollow\" class=\"caption-link\" href=\"https://www.gettyimages.com/detail/news-photo/jonathan-a-16-year-old-teenager-receives-a-dose-of-the-news-photo/1230743617?adppopup=true\">Getty | Jack Guez</a>)</p>  </figure><div><a name=\"page-1\"></a></div>\n<p>Adolescents aged 12 to 15 were completely protected from symptomatic COVID-19 after being vaccinated with the Pfizer/BioNtech mRNA vaccine in a small Phase III clinical trial, Pfizer reported in <a href=\"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-announce-positive-topline-results-pivotal\">a press release Wednesday</a>.</p>\n<p>The company also said that the vaccine was well tolerated in the age group, spurring only the standard side effects seen in people aged 16 to 25. The vaccine is already authorized for use in people aged 16 and over.</p>\n<p>The vaccine appeared more effective at spurring defensive immune responses in adolescents aged 12 to 15 than in the 16- to 25-year-old group, producing even higher levels of antibodies that were able to neutralize SARS-CoV-2. In a measure of neutralizing antibodies, vaccinated youths in the new trial had geometric mean titers (GMTs) of 1,239.5, compared with the GMTs of 705.1 previously seen in those aged 16 to 25, Pfizer noted.</p></div><p><a href=\"https://arstechnica.com/?p=1753451#p3\">Read 5 remaining paragraphs</a> | <a href=\"https://arstechnica.com/?p=1753451&comments=1\">Comments</a></p>","author":"Beth Mole","siteTitle":"Ars Technica","siteHash":"5b0ddf6e8923e49262a7894cfd77962733e43fbcc565a103b48373820b310636","entryHash":"f783bfc33dccde3d8a0c496096d8c34a5f75870e3a8591f85a6b7205c43209e9","category":"Tech"}